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Lactobacilli are generally regarded as safe; however, certain strains have been associated with cases of infection. Our workgroup
has already assessed many functional properties of Lactobacillus kefiri, but parameters regarding safety must be studied before
calling them probiotics. In this work, safety aspects and antimicrobial activity of L. kefiri strains were studied. None of the L. kefiri
strains tested caused 𝛼- or 𝛽-hemolysis. All the strains were susceptible to tetracycline, clindamycin, streptomycin, ampicillin,
erythromycin, kanamycin, and gentamicin; meanwhile, two strains were resistant to chloramphenicol. On the other hand, all L.
kefiri strains were able to inhibit both Gram(+) and Gram(−) pathogens. Regarding the in vitro results, L. kefiri CIDCA 8348
was selected to perform in vivo studies. Mice treated daily with an oral dose of 108 CFU during 21 days showed no signs of pain,
lethargy, dehydration, or diarrhea, and the histological studies were consistent with those findings. Moreover, no differences in
proinflammatory cytokines secretion were observed between treated and control mice. No translocation of microorganisms to
blood, spleen, or liver was observed. Regarding these findings, L. kefiri CIDCA 8348 is a microorganism isolated from a dairy
product with a great potential as probiotic for human or animal use.
1. Introduction
Kefir grains are composed of a complex community of yeasts,
lactic acid, and acetic acid bacteria confined in a matrix of
polysaccharides and proteins [1]. The product obtained by
fermentation of milk using these grains is called “kefir” and
several health-promoting properties have been associated to
its consumption [2–5].
As it is known, probiotics are “live microorganisms
which, administered in adequate amounts, exert a beneficial
effect to the health of the host” [6]. Specific strains of lactic
acid bacteria, in particular some of the genera Lactobacillus,
are extensively used as probiotics [7, 8] since their ability to
modulate the immune system has been demonstrated [9, 10]
as well as their capacity to inhibit the growth or invasion of
pathogenic bacteria and parasites [11–13].
The study of the beneficial properties attributed to iso-
lated microorganisms constitutes a field of great interest
for the development of functional foods. Lactobacilli are
generally regarded as safe (GRAS) and most of them (as Lac-
tobacillus kefiri) are included in the QPS list of the European
Union [14] due to their long history of use in fermented
dairy products and their presence in human intestinal tract.
However, certain Lactobacillus strains have been associated
with cases of sepsis, endocarditis, or bacteremia, mostly in
association with a severe underlying disease [15–18]. On
the other hand, the absence of the acquired antimicrobial
resistance is a very important criterion for evaluating the
safety of lactic acid bacteria (LAB) used as food started or
probiotics [19]. The breakpoints for the antibiotic list were
defined by the European Food Safety Authority (EFSA) in
order to assess the bacterial resistance to antibiotics of human
or veterinary importance [20, 21].
Our workgroup has isolated and characterized numerous
species of LAB and yeasts from kefir, including several strains
of Lactobacillus kefiri [22–24], one of the most predominant
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Table 1: Minimum inhibitory concentrations (MIC) for antibiotic resistance.
Antibiotics MIC (mg L
−1)
Breakpointsa CIDCA 8321 CIDCA 8345 CIDCA 8348 CIDCA 83115 CIDCA 83111 CIDCA 83113
Ampicillin 2 <0.032 <0.032 <0.032 <0.032 <0.032 <0.032
Clindamycin 1 <0.032 <0.032 <0.032 <0.032 <0.032 <0.032
Chloramphenicol 4 8 16 2 2 1 2
Erythromycin 1 <0.125 <0.125 <0.125 <0.125 <0.125 <0.125
Gentamicin 16 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
Kanamycin 32 <2 <2 <2 <2 <2 <2
Streptomycin 64 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
Tetracycline 8 <0.125 <0.125 4 2 4 <0.125
aThese are the recommended breakpoints for heterofermentative lactobacilli EFSA Panel on Additives and Products or Substances used in Animal Feed (2012)
[20].
species present in kefir-fermented milk (ranged from 2 × 108
to 1 × 109 L. kefiri cells mL−1) [25].
We have already demonstrated the potential of L. kefiri
as a probiotic microorganism in vitro after verifying that
secretion products and surface proteins from these hetero-
fermentative lactobacilli exert a protective action against
the invasion of Salmonella enterica serovar Enteritidis [26]
and that they are able to antagonize the cytotoxic effects of
clostridial toxins on Vero cells [27]. On the other hand, it has
been demonstrated that L. kefiri strains are able to preserve a
high percentage of viability after both spray-drying [28, 29]
and freeze-drying procedures [30]. However, no parameter
regarding L. kefiri’s safety was ever evaluated. Since it is
known that both the beneficial properties such as harmful
characteristic are dependent on the strain, the individual
study of the safety of potential probiotic microorganisms
should be considered.
Taking into account the potential of L. kefiri as a novel
probiotic, we reported in thiswork some safety characteristics
of L. kefiri strains, as well as the capacity of strains to produce
antimicrobial compounds against some intestinal pathogens.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions. Pure cultures
used in this study comprised Lactobacillus kefiri strains
CIDCA 8321, 8345, 8348, 83111, 83113, and 83115 [23, 31].
These bacteria were cultured in MRS (Difco, Detroit, USA)
for 48 h at 37∘C. The following pathogenic bacteria were
also used, Enterococcus faecalis ATCC 29212, Staphylococcus
aureusATCC 6538, Shigella flexneriATCC 9199, Pseudomona
aeruginosaATCC 15442, a clinical isolate of Salmonella enter-
ica serovar Enteritidis CIDCA 101 (Hospital de Pediatr´ıa Pro-
fessor Juan P. Garrahan, Buenos Aires, Argentina), enterohe-
morrhagic Escherichia coli EDL 933, Listeria monocytogenes
ATCC 7644, and Bacillus cereus ATCC 10876. All mentioned
strains, except B. cereus, were grown using brain heart
infusion (BHI) broth (Biokar Diagnostics, Beauvais, France)
in agitation at 37∘C for 16 h. B. cereus was grown in BHI
growth supplemented with dextrose (Anedra, Argentina)
1 g L−1 (BHIg) in agitation at 37∘C for 16 h.
2.2. Hemolysis. Hemolysis was tested by growth of the
strains on LAPTg agar (peptone 15 g L−1; tryptone 10 g L−1;
dextrose 10 g L−1; yeast extract 10 g L−1; Tween 80 1 g L−1;
and bacteriological agar 15 g L−1) supplemented with 5%
human blood (group O) and incubated for 48 h at 37∘C
under aerobic conditions. The appearance of clear zones
around the bacterial colonies indicated the presence of 𝛽-
hemolysiswhereas green zones around the colonies suggested
𝛼-hemolysis. Enterococcus faecalis ATCC 29212 was included
as a positive hemolytic control.
2.3. Minimum Inhibitory Concentration (MIC) for Antibi-
otic Resistance. The minimum inhibitory concentrations
(MICs) of the antimicrobial agents tested (Table 1) were
determined by broth microdilution according to the ISO
10932/IDF 233 standard from 2010 [32]. All antibiotics
(Sigma-Aldrich, USA) were dissolved for preparing stock
solutions of 1280𝜇gmL−1. Stock solutions were diluted in
LSM broth (90% IST plus 10%MRS) to obtain solutions with
preliminary concentrations in the range of 0.25–128 𝜇gmL−1.
Bacterial inocula were prepared by suspending colonies
from 48 h incubated in MRS medium to 5mL 0.85% NaCl
solution. Subsequently, inocula were adjusted to OD
625 nm
0.18–0.24 and diluted 1 : 500 in LSM broth for inoculation
of microdilution plates by adding 50𝜇L of diluted inoculum
to each well containing 50 𝜇L of an antibiotic solution. In
these conditions, the bacterial inoculum was around 2-3 ×
105 CFUmL−1 in the wells. After incubating plates under
anaerobic conditions at 37∘C for 48 hours, theMICs valuewas
read as the lowest concentration of an antimicrobial agent in
which visible growth was inhibited.
MICs results were compared with the recommended
breakpoints for heterofermentative lactobacilli by the EFSA
Panel on Additives and Products or Substances used in
Animal Feed [20].
2.4. PCR Detection of Chloramphenicol Resistance Gene. Cat,
chloramphenicol acetyltransferase gene, was assessed using
the primers and PCR conditions described by Hummel et
al. [33]. A plasmid from L. reuteri G4 was used as a positive
control.
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2.5. Growth Inhibition of Bacterial Pathogens. The agar spot
test described by Schillinger and Lu¨cke [34] was used. Briefly,
5 𝜇L of a suspension OD
625 nm 1 of L. kefiri strains was spotted
into MRS agar and incubated for 24 h at 37∘C. The following
day, pathogens were seeded into soft BHI agar and plated over
the spotted lactobacilli. After 18 h of incubation at 37∘C, the
inhibition halos were measured. The width of the clear zone
(𝑅) was calculated as follows: 𝑅 = (dInhib − dSpot)/2, where
dInhib is the diameter of the zone without pathogen growth
and dSpot is the diameter of the spot. Inhibition scores are
as follows: negative (−), 𝑅 < 2mm; low inhibition capacity
(+), 2mm < 𝑅 < 5mm; and high inhibition capacity (++),
𝑅 > 6mm. At least three independent experiments were
performed.
2.6. In Vivo Studies
2.6.1. Ethics Statement. All animal procedures were per-
formed in strict accordance with the guidelines issued by the
European Economic Community “86/609.”
2.6.2. Experimental In Vivo Protocol. Male 6-week-old Swiss
albino mice (Janvier, Le Genest Isle, France) were quaran-
tined 2 weeks after arrival and then randomized by body
weight into experimental and control groups of 5–7 animals
each. Mice were housed under standard laboratory condi-
tions with free access to food and water. The temperature
was kept at 22∘C and a 12-hour light/dark schedule was
maintained. Mice received by gavage 108 CFU of L. kefiri
CIDCA 8348 (Lk group) or PBS (control group) daily for 21
days.
2.6.3. Safety Evaluation. Mice were weighted every two days;
behavior and signs of pain were analyzed daily [35]. At
the end of the experimental protocol, ileum and colon
were removed and histological studies were performed using
hematoxylin-eosin staining [36].
2.6.4. Translocation Assay. Liver and spleen were removed
and blood sampleswere collected aseptically. Liver and spleen
were homogenized in 0.1% sterile PBS (0.1 g of organ per mL)
and serially diluted. One hundred microliters of each organ
homogenate or blood was plated on VRBG Agar (Biokar
Diagnostics, Beauvais, France) for enterobacteria and MRS
agar for LAB. Plates were incubated under aerobic conditions
for 24 h at 37∘C for VRBG and for 48 h at 37∘C forMRS before
examination.
2.6.5. Microorganism Counts in the Ileum. Ileum content was
washed with 1mL sterile PBS and then serial dilutions were
plated as indicated above.
2.6.6. Cytokine Release by Intestine and Colon Explants.
Explants were cultured in RPMImedium supplemented with
10% foetal bovine serum (Gibco-Invitrogen, Carlsbad, CA,
USA), 10mg/L streptomycin and 10 IU/mL penicillin G, and
100mg/L gentamicin (all from SigmaChemical Co., St. Louis,
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Figure 1: Body weight gain of treated (Lk) and control mice along
21 days of L. kefir CIDCA 8348 administration. No differences were
observed between control mice and Lk mice (𝑃 > 0.05).
MO, USA) for 24 h at 37∘C in a 5% (v/v) CO
2
-95% (v/v)
air atmosphere [37, 38]. Supernatants were collected, cen-
trifuged, and frozen for cytokines (IL-6, IL-17A, TNF-𝛼,
IFN-𝛾, and GM-CSF) measurements (eBioscience Ready Set
Go, France). All assays were performed according to the
manufacturer’s instructions.
3. Results and Discussion
In the present work, six potentially probiotic L. kefiri strains
isolated fromkefirwere studied in order to evaluate both their
safety and antimicrobial properties.
Since hemolysis is a common virulence factor among
pathogens, the first safety parameter evaluated in vitro was
bacterial hemolytic activity. In this study, none of the L. kefiri
strains tested caused 𝛼- or 𝛽-hemolysis (data not shown). In
this genus, hemolytic activity has a very low frequency and
only 𝛼-hemolysis has been reported for lactobacilli isolated
from foods and dairy products [39–41].
Another important feature regarding safety is the sensi-
tivity to antibiotics. The results obtained for L. kefiri strains
are shown in Table 1. All tested bacteria exhibited MIC
values lower than the breakpoints recommended for hetero-
fermentative lactobacilli [20] for tetracycline, clindamycin,
streptomycin, ampicillin, erythromycin, kanamycin, and gen-
tamicin. However, the strains CIDCA 8321 and 8345 were
resistant to chloramphenicol although the amplification of
CAT encoding gene was negative for all the L. kefiri strains
(data not shown). In this regard, Hummel et al. [33] reported
that some lactobacilli strains carrying cat genes were sus-
ceptible to chloramphenicol; meanwhile, in other resistant
strains cat genes could not be amplified. Further research,
such as the study of the distribution of chloramphenicol
MICs, could contribute to determine whether resistance
is acquired (not acceptable strain) or intrinsic (acceptable
strain) according to EFSA [21].
To our knowledge, antibiotic sensitivity of L. kefiri was
evaluated just in two publications. Nawaz et al. [42] studied
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Table 2: Antimicrobial activity of Lactobacillus kefiri strains against pathogens by agar spot test.
Growth inhibition ability
Strain CIDCA 8321 CIDCA 8345 CIDCA 8348 CIDCA 83115 CIDCA 83111 CIDCA 83113
Gram negative bacilli
Pseudomona aeruginosa ++ + ++ + + +
SalmonellaEnteritidis + − + − + +
Shigella flexneri + − + − + −
EHEC − − − − − −
Gram positive bacilli
Listeria monocytogenes + − + − + −
Bacillus cereus ++ + ++ + + ++
Gram positive cocci
Enterococcus faecalis + − + − − −
Staphylococcus aureus ++ + ++ + ++ +
100𝜇m
(a)
100𝜇m
(b)
100𝜇m
(c)
100𝜇m
(d)
Figure 2: Hematoxylin-eosin staining of ileum and colon section. (a) Ileum of control mice; (b) ileum of mice receiving L. kefiri CIDCA
8348 for 21 days; (c) colon of control mice; (d) colon of mice receiving L. kefiri CIDCA 8348 for 21 days. No differences were observed among
groups in any tissue.
one L. kefiri strain isolated from a dairy product, which was
resistant to kanamycin and tetracycline but sensitive to other
antimicrobial agents tested in LSMmedium. Chang et al. [43]
observed that all the L. kefiri strains, among other lactobacilli,
isolated from swine intestines were resistant to tetracycline,
with MIC values higher than 256𝜇gmL−1, and that they
possessed at least one resistance gene. Taking into account
that tetracycline is the most widely used antimicrobial agent
in swine production, its continuous administration might
be selecting tetracycline resistant microorganisms on swine’s
microbiota. This feature and the different origin of our
L. kefiri strains could contribute, at least in part, to the
disagreement between our results and those from other
authors.
The secretion of molecules able to inhibit the growth of
pathogens is a desirable characteristic, among others, for a
potentially probiotic bacteria [44], and it could also be a
technological advantage in the food industry since theymight
be used as functional starter cultures [45, 46]. We evaluated
the pathogen growth inhibition capacity of the six L. kefiri
strains studied. As observed in Table 2, the inhibition profile
was strain dependent, and Gram positive pathogens showed
higher sensibility to L. kefiri strains than Gram negative
bacteria. It is important to notice that the addition of MRS
acidified with HCl or lactic acid to pH 4.3 (final pH reached
by L. kefiri cultures) was not able to produce inhibition
of pathogens in our tests (data not shown). All the strains
inhibited growth of Bacillus cereus and Staphylococcus aureus
but none of them inhibited enterohemorrhagic Escherichia
coli (EHEC). The strains L. kefiri CIDCA 8321, CIDCA 8348,
and CIDCA 83111 were able to inhibit growth of the rest
of the tested pathogens. Many mechanisms associated with
bacterial inhibition have been described for Lactobacillus
species [47]. The production of antimicrobial molecules is
usually strain dependent, which is in accordance with our
results, and the introduction of probiotic bacteria able to
inhibit other microorganisms could have a positive impact in
animal and human health [48, 49].
Up to here, L. kefiri CIDCA 8321, 8348, and 83111
demonstrated to be themost active strains against pathogens;
however, CIDCA8321 showed resistance to chloramphenicol.
In consequence, among the other two strains, we selected
CIDCA 8348 to perform in vivo studies in Swiss mice.
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Figure 3: Secretion of proinflammatory cytokines by intestine and colon explants frommice receiving L. kefiri CIDCA 8348 for 21 days (Lk)
and control mice determined by ELISA. Statistical analysis: one way ANOVA, posttest Bonferroni, 𝛼 = 0.05.
As observed in Figure 1, no differences in body weight
were observed between mice that received 100 𝜇L of a
109 CFUmL−1 suspension of L. kefiriCIDCA8348 (Lk group)
and mice receiving 100 𝜇L of PBS (control group) daily for
21 days. Moreover, there were no differences in food and
water intake between groups (data not shown). In accordance
with these results, Lk group did not show any signs of
pain, lethargy, dehydration, or diarrhea during treatment.
No signs of inflammation or damage were observed in any
organ during necropsy. Length of each mouse’s colon was
measured, since it has been reported that increasing levels
of inflammation result in shortening of the colon [50]. No
significant differences in colon’s length of Lkmice and control
mice were observed (12.4 ± 0.6 versus 12.6 ± 0.8). Moreover,
the histological study of ileum and colon was consistent with
the already described observations; no signs of inflammation,
edema, erosion/ulceration, crypt loss, or infiltration ofmono-
and polymorphonuclear cells [51] were observed in Lk mice’s
tissues (Figure 2), in concordance with previous report by
Bolla et al. [30] who administered this strain as a constituent
of a mixture of five kefir-isolated microorganisms to BALB/c
mice. Additionally, no differences in the secretion levels
for proinflammatory cytokines such as IL-6, IL-17A, IFN-𝛾,
TNF-𝛼, and GM-CSF were observed in the small intestine
and colon explants from Lk and control mice (Figure 3).
On the other hand, no translocation of microorganisms was
observed on blood, spleen, or liver (bacterial counts were
negative), which means that the epithelial barrier was not
disrupted since intestinal permeability was not affected by L.
kefiri CIDCA 8348 administration [52]. Besides, the viable
counts of enterobacteria (3.5±0.8×107 versus 4.8±0.9×107)
and LAB (1.1 ± 0.6 × 107 versus 2.6 ± 0.8 × 107) in the ileum
were comparable between control and treated mice.
4. Conclusion
Taking into account all these findings, we conclude that L.
kefiri CIDCA 8348 isolated from a dairy product present a
great potential as probiotic for human or animal use and can
be used also for producing functional foods.
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